Fax: (713) 563-9586.
Differences between a drug regimen employed in early phase 1 trials and the subsequent use of the agent in routine oncologic practice
A note of caution
Article first published online: 20 AUG 2007
Copyright © 2007 American Cancer Society
Volume 110, Issue 8, pages 1644–1647, 15 October 2007
How to Cite
Markman, M. (2007), Differences between a drug regimen employed in early phase 1 trials and the subsequent use of the agent in routine oncologic practice. Cancer, 110: 1644–1647. doi: 10.1002/cncr.22967
- Issue published online: 19 SEP 2007
- Article first published online: 20 AUG 2007
- Manuscript Accepted: 24 APR 2007
- Manuscript Received: 18 APR 2007
It is reasonable to assume that a decision to permit wider access to new anticancer agents after the completion of only phase 1 trials will almost certainly result in the administration of such therapy to a substantial population of individuals who would not have been eligible for such “registration-type” testing. However, the optimal use of antineoplastic agents in routine clinical practice may differ substantially from the doses and schedules examined in phase 1 clinical trials.